Lantern Pharma Engages IBN to Enhance Corporate Communications Strategy for AI-Driven Oncology Pipeline

Lantern Pharma (NASDAQ: LTRN), a biotechnology company utilizing its RADR® AI platform to accelerate precision oncology drug development, has engaged InvestorWire (IBN) to lead its corporate communications strategy. The company is currently advancing clinical programs targeting lung, brain, breast, and blood cancers, including three AI-guided drug candidates and a central nervous system-focused subsidiary. These programs include multiple therapies that have received FDA designations and are currently in active clinical trials.

The partnership with IBN aims to expand investor awareness as Lantern pursues key milestones across its data-driven, biomarker-informed pipeline. Lantern Pharma's proprietary AI and machine learning platform, RADR®, leverages over 200 billion oncology-focused data points and a library of more than 200 advanced machine learning algorithms to address real-world challenges in oncology drug development. This engagement represents a strategic move to enhance visibility during a critical period of clinical advancement.

The importance of this partnership lies in its potential to improve communication about Lantern's innovative approach to drug development. By working with a specialized communications platform like IBN, which provides advanced wire-grade press release syndication and access to a network of over 5,000 outlets, Lantern can more effectively reach investors, journalists, and the broader investment community. This enhanced communication strategy could facilitate better understanding of the company's AI-driven approach to accelerating cancer drug development.

Lantern's drug development model has demonstrated significant efficiency gains, with newly developed programs advancing from initial AI insights to first-in-human clinical trials in just 2-3 years at approximately $2.5 million per program. The company's newsroom, available at https://ibn.fm/LTRN, provides ongoing updates about these developments. The partnership with IBN, which is part of a dynamic brand portfolio delivering comprehensive corporate communications solutions, could help showcase these achievements to a wider audience.

This collaboration matters because effective communication about innovative biotechnologies is crucial for attracting investment and building confidence in novel approaches to drug development. As Lantern advances its pipeline of therapies spanning multiple cancer indications, including both solid tumors and blood cancers, clear and widespread communication about progress and milestones becomes increasingly important for both scientific and investment communities.